Fundraising Fox
Biotheryx
San Diego, US · Founded 2008 · California corporation · 27 employees on LinkedIn · 3 known investors
Find your way into Biotheryx
Sign up to see every warm intro you have to Biotheryx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Biotheryx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease. Its drug discovery work is built on modulating Cereblon and its proprietary PRODEGY platform.
Founders & leadership
KC
Kyle Chan, PhDExecutive
FM
Frank Mercurio, PhDExecutive
RW
Raymond W. UrbanskiActing Chief Medical OfficerRaymond W. Urbanski holds an MD and PhD in Pharmacology from New Jersey Medical School and has spent over 25 years in clinical research, medical practice, and pharmaceutical development, including roles as Chief Medical Officer at GT Biopharma and MannKind Corporation, SVP of Clinical Development at Soleno Therapeutics, and positions at Pfizer spanning oncology clinical research and established products.
PD
Philippe DrouetChief Executive OfficerPhilippe Drouet held the position of Chief Commercial Officer at CRISPR Therapeutics, where he oversaw commercial strategy and organization development. He is now CEO of Biotheryx, a clinical-stage biopharmaceutical company developing targeted protein degraders for cancer and inflammatory disease.
DS
David Stirling, PhDNamed on SEC filing
Board
LD
Louis DeGennaro, PhDBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$93.8M disclosed across 4 rounds · 2014–2021
▶$92.1MraisedJun 2021 · 40 investors · BiotechnologyRule 506(b)
▶$92.1MraisedJun 2021 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kyle W.H. ChanExecutive Officer
- Dung ThaiExecutive Officer
- Jack NoelkeDirector
- Christopher DevineDirector
- Jaime A. DonadioExecutive Officer
- Louis DeGennaroDirector
- David I. StirlingExecutive Officer, Director
- Frank MercurioExecutive Officer
- Robert F. WilliamsonExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $92.1M
- First sale
- May 2021
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$500KraisedMay 2015 · 4 investors · BiotechnologyRule 506(b)
▶$500KraisedMay 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kyle Chan, PhDExecutive Officer
- David Stirling, PhDExecutive Officer, Director
- Louis DeGennaro, PhDDirector
- Lawrence ZaslowExecutive Officer, Director
- Frank Mercurio, PhDExecutive Officer
- Offering amount
- $6M
- Amount sold
- $500K
- Minimum investment
- $50K
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150KraisedSep 2014 · 3 investors · BiotechnologyRule 506(b)
▶$150KraisedSep 2014 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Louis DeGennaro, PhDDirector
- Frank Mercurio, PhDExecutive Officer
- Kyle Chan, PhDExecutive Officer
- Lawrence ZaslowExecutive Officer, Director
- David Stirling, PhDExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $150K
- Minimum investment
- $25K
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedJun 2014 · 10 investors · BiotechnologyRule 506(b)
▶$1MraisedJun 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank Mercurio, PhDExecutive Officer
- Lawrence ZaslowExecutive Officer, Director
- David Stirling, PhDExecutive Officer, Director
- Louis DeGennaro, PhDDirector
- Kyle Chan, PhDExecutive Officer
- Offering amount
- $5M
- Amount sold
- $1M
- Minimum investment
- $50K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Nurix TherapeuticsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
UltragenyxUltragenyx is a biotechnology company focused on developing treatments for patients living with rare genetic diseases. The company emphasizes a culture of generosity, curiosity, and inclusion among its team members.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies working in the same space as Biotheryx.
Frequently asked questions
- What does Biotheryx do?
- Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease. Its drug discovery work is built on modulating Cereblon and its proprietary PRODEGY platform.
- Who are Biotheryx's investors?
- Biotheryx's investors include Lumira Ventures, Revelation Partners, SR One Capital Management.
- How much funding has Biotheryx raised?
- Biotheryx has disclosed $93.8M raised across 4 rounds.
- Where is Biotheryx headquartered?
- Biotheryx is headquartered in San Diego, US.